Company / SG&A Expense
Pacira BioSciences, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$368.8M
FY2025
5-year range
$200.8M / $368.8M
FY2021-FY2025
Trend
+25.4%
vs FY2024
Sector context
#47 of 213
Health Care
What the data says
Pacira BioSciences, Inc.'s sg&a expense of $369M is higher than 78% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 8 consecutive years, from $139M in FY2017 to $369M in FY2025.
Based on SEC 10-K filings.
$369M in FY2025 with a 5-year CAGR of +15.8%. Top quartile in the Health Care sector.
Increased from $269M to $369M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +13.2%
- 5-Year CAGR
- +15.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 213This company $368.8M Sector average $722.3M
▼
-48.9% below sector average
Key checks
Key Insights
- Pacira BioSciences, Inc.'s sg&a expense has grown for 8 consecutive years.
- 5-year CAGR of +15.8%, indicating consistent growth.
- In FY2025, sg&a expense increased 25.4% year-over-year.
- Ranks #47 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Negative profit margin: -14.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $368.8M | +25.4% |
| FY2024 | $294.1M | +9.2% |
| FY2023 | $269.4M | +5.9% |
| FY2022 | $254.5M | +26.8% |
| FY2021 | $200.8M | +13.3% |
| FY2020 | $177.3M | +9.8% |
| FY2019 | $161.5M | +5.8% |
| FY2018 | $152.6M | +9.8% |
| FY2017 | $139.0M | -8.9% |
| FY2016 | $152.6M | +9.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026